FDA approves first treatment for MCT8 Deficiency

The U.S. FDA has approved Emcitate (tiratricol) to treat peripheral thyrotoxicosis, the first FDA-approved therapy for MCT8 Deficiency. The condition causes symptoms such as rapid heart rate, increased blood pressure, and metabolic disruptions.